Nuformix plc

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
Deal price
0.05
Discount of 68 %
Last Price 0.155p p

Key information

Key information

Sector

Pharmaceuticals

Close date

Delivery

Placing price

Last price

Discount

Amount raised

0.05

0.155 p

68 %

£300,000

Use of proceeds

The net proceeds of the Fundraise will be used by the Company primarily to drive forward partnering discussions for its NXP002 programme, an inhaled treatment for idiopathic pulmonary fibrosis ("IPF") and progressive pulmonary fibrosis ("PPF"), as well as to provide funding for general corporate purposes.

Important notices

This website contains links to other websites and resources provided by third parties. These links are provided for your information only and we accept no responsibility for them or for any loss or damage that may arise from your use of them.

Investing in financial products involves taking risk. The value of investments can go up as well as down and you may receive back less than your original investment. CMC Markets UK plc trading as CMC CapX (“CMC”) does not provide investment advice of any kind and individual investors should make their own decisions or seek independent advice regarding the merits of entering into, and the suitability of, any investment. Nothing on this website and no communication from CMC should be construed as an investment recommendation. Only professional clients and eligible counterparties are eligible to participate in any offering in connection with CMC's services. There are inherent risks associated with investing in such offerings and such investments should only be made as part of a diversified portfolio. Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful.

Please read our Risk Warning before making any investment decisions.

Capx

Participate in exclusive deals

Start investing in exclusive deals.